Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model

References

• LambertsLEKochMde JongJSTumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility studyClin Cancer Res201723112730274128119364
   PubMed Web of Science ®Google Scholar
• UnkartJTChenSLWapnirILGonzalezJEHarootunianAWallaceAMIntraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase 1 studyAnn Surg Oncol Epub2017711
   Web of Science ®Google Scholar
• CendanJCCocoDCopelandEM3rdAccuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed marginsJ Am Coll Surg2005201219419816038815
   PubMed Web of Science ®Google Scholar
• NguyenQTOlsonESAguileraTASurgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survivalProc Natl Acad Sci U S A201010794317432220160097
   PubMed Web of Science ®Google Scholar
• WeisslederRPittetMJImaging in the era of molecular oncologyNature2008452718758058918385732
   PubMed Web of Science ®Google Scholar
• WhitleyMJCardonaDMLazaridesALA mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancerSci Transl Med20168320320ra4
   PubMed Web of Science ®Google Scholar
• ChiCZhangQMaoYIncreased precision of orthotopic and metastatic breast cancer surgery guided by matrix metalloproteinase-activatable near-infrared fluorescence probesSci Rep201551419726395067
   PubMed Web of Science ®Google Scholar
• RosenthalELWarramJMde BoerESafety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancerClin Cancer Res201521163658366625904751
   PubMed Web of Science ®Google Scholar
• HoganBVPeterMBShenoyHGHorganKHughesTASurgery induced immunosuppressionSurgeon201191384321195330
   PubMed Web of Science ®Google Scholar
• KwonEDFosterBAHurwitzAAElimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapyProc Natl Acad Sci U S A19999626150741507910611340
   PubMed Web of Science ®Google Scholar
• DrakeCGJaffeeEPardollDMMechanisms of immune evasion by tumorsAdv Immunol200690518116730261
   PubMed Web of Science ®Google Scholar
• FridmanWHPagesFSautes-FridmanCGalonJThe immune con-texture in human tumours: impact on clinical outcomeNat Rev Cancer201212429830622419253
   PubMed Web of Science ®Google Scholar
• NguyenLTOhashiPSClinical blockade of PD1 and LAG3–potential mechanisms of actionNat Rev Immunol2015151455625534622
   PubMed Web of Science ®Google Scholar
• OhaegbulamKCAssalALazar-MolnarEYaoYZangXHuman cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathwayTrends Mol Med2015211243325440090
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• AgataYKawasakiANishimuraHExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInt Immunol1996857657728671665
   PubMed Web of Science ®Google Scholar
• ButteMJKeirMEPhamduyTBSharpeAHFreemanGJProgrammed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responsesImmunity200727111112217629517
   PubMed Web of Science ®Google Scholar
• FliesDBSandlerBJSznolMChenLBlockade of the B7-H1/PD-1 pathway for cancer immunotherapyYale J Biol Med201184440942122180678
   PubMedGoogle Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• OkazakiTChikumaSIwaiYFagarasanSHonjoTA rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNat Immunol201314121212121824240160
   PubMed Web of Science ®Google Scholar
• RadvanyiLPilon-ThomasSPengWAntagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer–letterClin Cancer Res20131919554124048330
   PubMed Web of Science ®Google Scholar
• TumehPCHarviewCLYearleyJHPD-1 blockade induces responses by inhibiting adaptive immune resistanceNature2014515752856857125428505
   PubMed Web of Science ®Google Scholar
• ShethRAArellanoRSUppotRNProspective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesionsRadiology2015274391792625302707
   PubMed Web of Science ®Google Scholar
• NatarajanAMayerATXuLReevesREGanoJGambhirSSNovel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytesBioconjug Chem201526102062206926307602
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• MittendorfEAPhilipsAVMeric-BernstamFPD-L1 expression in triple-negative breast cancerCancer Immunol Res20142436137024764583
   PubMed Web of Science ®Google Scholar
• ChawlaAPhilipsAVAlatrashGMittendorfEImmune checkpoints: a therapeutic target in triple negative breast cancerOncoimmunology201433e2832524843833
   PubMedGoogle Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• BarberDLWherryEJMasopustDRestoring function in exhausted CD8 T cells during chronic viral infectionNature2006439707768268716382236
   PubMed Web of Science ®Google Scholar